Sertindole: cardiac electrophysiological profile
International Journal of Psychiatry in Clinical Practice
|June 17, 2014
Summary
QT interval prolongation, a marker of cardiac action potential duration, can increase ventricular tachycardia risk. Sertindole, an antipsychotic, shows a low proarrhythmic potential due to its balanced electrophysiological profile.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- QT interval prolongation on ECG correlates with cardiac action potential prolongation.
- This prolongation is linked to increased ventricular tachycardia risk, particularly with certain drugs and congenital long QT syndrome.
- Most QT-prolonging drugs inhibit the rapid component of the delayed rectifier potassium current (I Kr), crucial for cardiac repolarization.
Purpose of the Study:
- To investigate the electrophysiological profile of the antipsychotic sertindole.
- To assess sertindole's potential for QT interval prolongation and associated proarrhythmic risk.
- To understand the mechanisms underlying sertindole's cardiac safety profile.
Main Methods:
- Evaluation of sertindole's effects on the rapid component of the delayed rectifier potassium current (I Kr).
- Assessment of sertindole's interactions with other ion channels (sodium, calcium) and receptors (α1-adrenoceptors).
- Comparison of sertindole's proarrhythmic potential in animal models against known proarrhythmic drugs.
Main Results:
- Sertindole inhibits I Kr, but possesses a balanced electrophysiological profile.
- Sertindole also inhibits α1-adrenoceptors and blocks sodium and calcium channels.
- This balanced profile correlated with low proarrhythmic potential in animal models and no increased cardiac mortality in clinical studies.
Conclusions:
- Sertindole's unique electrophysiological counterbalance mitigates the proarrhythmic risk associated with I Kr inhibition.
- The drug's multi-channel and receptor interactions contribute to its favorable cardiac safety profile.
- Clinical and epidemiological data support the low cardiac risk observed with sertindole treatment.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:19Electrophysiology of Normal Cardiac Rhythm
7.8K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
7.8K
01:28Mechanism of Cardiac Arrhythmias
2.7K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K